Patents Examined by Karen Cheng
-
Patent number: 11970439Abstract: An 8-(4-chlorobenzylideneamino)naphthalene-1,3-disulfonic acid compound, its synthesis, and its use as an antioxidant agent.Type: GrantFiled: October 30, 2023Date of Patent: April 30, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
-
Patent number: 11970440Abstract: An 8-(3-chlorobenzylideneamino)naphthalene-1,3-disulfonic acid compound, its synthesis, and its use as an antioxidant agent.Type: GrantFiled: October 30, 2023Date of Patent: April 30, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
-
Patent number: 11970475Abstract: A 4-(1-(2-Hydroxypropyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-3-ol compound, its synthesis, and its use as an antimicrobial agent.Type: GrantFiled: September 5, 2023Date of Patent: April 30, 2024Assignee: KING FAISAL UNIVERSITYInventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Adel A. Marzouk
-
Patent number: 11970501Abstract: The present invention relates to highly polarizable 3D organic perovskites of the general formula ABX3, prepared by introducing halogen functional groups in the A-site cation (in which the A and B sites are occupied by organic cations and the X site is a monovalent non-metallic counterion). The (DCl)(NH4)(BF4)3 crystal exhibits a strong linear electrooptic (EO) effect with an effective EO coefficient of 20 pmV?1, which is 10 times higher than that of metal halide perovskites. These 3D organic perovskites are solution processed and compatible with silicon, and illustrate the potential of rationally-designed all-organic perovskites for use in on-chip modulators, electro-optic devices, piezoelectric devices, or silicon photonics devices.Type: GrantFiled: September 1, 2021Date of Patent: April 30, 2024Assignee: HUAWEI TECHNOLOGIES CANADA CO., LTD.Inventors: Meng-Jia Sun, Chao Zheng, Sjoerd Hoogland, Edward Hartley Sargent
-
Patent number: 11958976Abstract: Provided are a photoactive fluorophore, a photoactive ligand, and a photoactive complex. The photoactive fluorophore includes a photoactivatable derivative of an azetidine-containing Janelia-Fluor dye. The photoactive ligand includes a photoactive fluorophore and a protein tag. The photoactive complex includes a photoactive ligand conjugated to a protein. Also provided are methods of in vivo labeling with and photoactivation of the photoactive fluorophore, ligand, and complex.Type: GrantFiled: October 27, 2022Date of Patent: April 16, 2024Assignee: HOWARD HUGHES MEDICAL INSTITUTEInventors: Luke D. Lavis, Jonathan B. Grimm
-
Patent number: 11952355Abstract: Provided are a method of preparing a malononitrile oxime ether compound and an intermediate compound. The malononitrile oxime ether compound has a structure as shown in formula (VII), wherein W is selected from aryl or heteroaryl. The preparation method comprises: reacting a first raw material with a second raw material in the presence of a first solvent and a catalyst to obtain the intermediate compound, wherein the first raw material has a structure as shown in formula (IV), and the second raw material has a structure as shown in formula (V); and subjecting the intermediate compound, and a dehydrant to a dehydration reaction in the present of a second solvent to obtain the malononitrile oxime ether compound. Furthermore, the malononitrile oxime ether compound is obtained through one-step dehydration reaction. using the preparation method, is advantageous for improving the yield of malononitrile oxime ethers and reducing the cost.Type: GrantFiled: June 17, 2019Date of Patent: April 9, 2024Assignee: Shenyang Sinochem Agrochemicals R&D Co., Ltd.Inventors: Hongfei Wu, Xueming Cheng, Libao Xu, Chunxiao Guo, Jingbo Xu, Ningning Sun, Haibo Yu
-
Patent number: 11952397Abstract: This invention relates to crystalline forms of anhydrous Compound (1) and pharmaceutical compositions thereof. Also disclosed herein are methods of making crystalline solid forms of Compound (1), and methods of using the crystalline forms of Compound (1) and pharmaceutical compositions thereof for modulating GABA activity (e.g., positive allosteric modulation of GABA activity) and treating CNS-related disorders.Type: GrantFiled: August 2, 2023Date of Patent: April 9, 2024Assignee: Sage Therapeutics, Inc.Inventors: Shanming Kuang, Tianrui Li
-
Patent number: 11952357Abstract: The present disclosure relates to the field of epoxide resin, and more particularly to an epoxide with a low total chlorine content and no heavy metal residues, and a preparation method thereof. Disclosed is an epoxide prepared from raw materials including an unsaturated cycloaliphatic compound containing a double bond, hydrogen peroxide, an organic acid compound, a solvent and an alkaline salt; wherein a molar ratio of the organic acid compound to the unsaturated cycloaliphatic compound containing a double bond is (1-1.5):1. The obtained epoxides obtained in the present disclosure have a high purity, a high yield, a low solvent content, low chroma, and a low chlorine and metal ion content; the reaction system is simple, environmentally friendly, safe and controllable, and the production cost is low, which can meet the technical and economic requirements and are suitable for large-scale industrial production.Type: GrantFiled: September 17, 2020Date of Patent: April 9, 2024Assignee: JIANGSU TETRA NEW MATERIAL TECHNOLOGY CO., LTD.Inventors: Jianwei Han, Quan Jia, Yangjun Chang, Xiangming Cao
-
Patent number: 11939291Abstract: The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.Type: GrantFiled: April 9, 2021Date of Patent: March 26, 2024Assignees: University of Kansas, University of South FloridaInventors: Sanket Jaiprakash Mishra, Brian S. J. Blagg, Chad Anthony Dickey
-
Patent number: 11932594Abstract: An 8-((2-hydroxy-5-methylphenyl)diazenyl)naphthalene-1,3-disulfonic acid compound, its synthesis, and its use as an antioxidant agent.Type: GrantFiled: October 31, 2023Date of Patent: March 19, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
-
Patent number: 11926642Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.Type: GrantFiled: July 1, 2021Date of Patent: March 12, 2024Assignee: Pfizer inc.Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
-
Patent number: 11919896Abstract: Disclosed are a [1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and an application thereof in preparing a drug for treating a disease related to JAK1 or/and TYK2. Specifically, the present invention relates to a compound represented by formula (I), or an isomer or pharmaceutically acceptable salt thereof.Type: GrantFiled: August 23, 2019Date of Patent: March 5, 2024Assignee: ZHUHAI UNITED LABORATORIES CO., LTD.Inventors: Weiwei Mao, Wenyuan Qian, Xuejian Zheng, Guoping Hu, Changqing Wei, Jian Li, Shuhui Chen
-
Patent number: 11912679Abstract: [Problem] A compound which is useful as a STING inhibitor is provided. [Means for Solution] The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory action on STING and can be used as an agent for treating an autoimmune disease, a neurodegenerative disease, a type I interferonopathy and/or other STING-mediated disease.Type: GrantFiled: September 26, 2023Date of Patent: February 27, 2024Assignees: Astellas Pharma, Inc., Mitobridge, Inc.Inventors: Junko Maeda, Ikumi Kuriwaki, Kai Kitamura, Yumi Yamashita, Kenichi Kakefuda, Akio Kamikawa, Kenji Negoro, Wataru Hamaguchi, Ryushi Seo, Jeffrey Ciavarri
-
Patent number: 11905259Abstract: A 2-(benzo[d]oxazol-2-yl)-N?-(4-(dimethylamino)benzoyloxy)acetimidamide compound, its synthesis, and its use as an antimicrobial agent.Type: GrantFiled: October 23, 2023Date of Patent: February 20, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
-
Patent number: 11897898Abstract: Provided are compounds of Formula (I?), including compounds of Formulas (I), (II), (III), (IIIA) and (IIIB), wherein L, R1, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).Type: GrantFiled: August 13, 2019Date of Patent: February 13, 2024Assignee: BIOGEN MA INC.Inventor: Felix Gonzalez Lopez de Turiso
-
Patent number: 11866430Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK ?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.Type: GrantFiled: June 26, 2019Date of Patent: January 9, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Louis S. Chupak, Min Ding, Robert G. Gentles, Yazhong Huang, Scott W. Martin, Ivar M. Mcdonald, Stephen E. Mercer, Richard E. Olson, Upender Velaparthi, Michael Wichroski, Xiaofan Zheng
-
Patent number: 11858910Abstract: A pyridinylmethylenepiperidine derivatives and uses thereof, specifically, the present invention relates to a novel pyridinylmethylenepiperidine compound and a pharmaceutical composition containing this compound, which may be used for activating 5-HT1F receptor. The present invention also relates to methods of preparing this compound and pharmaceutical composition, and their use in the manufacture of a medicament for treating a 5-HT1F receptor-related disease, especially migraine.Type: GrantFiled: August 22, 2019Date of Patent: January 2, 2024Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Chuanfei Jin, Wenhe Zhong, Yaping Xue
-
Patent number: 11834425Abstract: A full continuous-flow preparation method of vitamin B1 includes: (S1) feeding 3-chloro-4-oxopentyl acetate, 2-methyl-4-amino-5-(aminomethyl) pyrimidine and carbon disulfide to a first continuous-flow reactor for addition; (S2) allowing the reaction mixture to flow into a first continuous filtration and reaction device to collect a filter cake; subjecting the filter cake and hydrochloric acid solution to cyclization; transporting the reaction mixture and an aqueous inorganic base solution to a micromixer and a second continuous-flow reactor for hydrolysis to obtain thiothiamine; (S3) transporting the thiothiamine to a third continuous-flow reactor with hydrogen peroxide for oxidation to obtain thiamine sulfate; and (S4) allowing the thiamine sulfate to enter a second continuous filtration and reaction device for filtration to collect a filter cake; and subjecting the filter cake to reaction with organic hydrochloric acid solution followed by filtration and drying to obtain vitamin B1.Type: GrantFiled: February 9, 2023Date of Patent: December 5, 2023Assignee: Fudan UniversityInventors: Fener Chen, Meifen Jiang, Minjie Liu, Yingqi Xia, Weijian Li
-
Patent number: 11186580Abstract: The present invention relates to salts and crystalline forms of 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, and crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, which are PI3K inhibitors useful in the treatment of cancer and other diseases.Type: GrantFiled: September 4, 2019Date of Patent: November 30, 2021Assignee: Incyte CorporationInventors: Brent Douty, David M. Burns, Andrew P. Combs, Zhongjiang Jia, Daniel Levy, Eddy W. Yue
-
Patent number: 11173144Abstract: Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with ?1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.Type: GrantFiled: May 12, 2017Date of Patent: November 16, 2021Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mehrdad Shamloo, Alam Jahangir, Bitna Yi, Andrew Kelley Evans, Michael John Green